目的:在卵巢中等反应和高反应患者中,比较2 000 IU、3 000 IU低剂量hCG与5 000 IU hCG在控制性超促排卵(COH)过程中诱导卵泡成熟及随后冷冻胚胎移植(FET)的妊娠结局。方法:回顾性分析2 166例接受IVF/ICSI治疗的患者的临床资料,根据hCG的剂量分为3组:2 000 IU(A组,n=722),3 000 IU(B组,n=722)和5 000 IU(C组,n=722),观察比较成熟卵母细胞的比例、受精率、临床妊娠率、累计妊娠率及卵巢过度刺激综合征(OHSS)的发生率等。结果:3组患者获得成熟卵母细胞比例(89.92%,91.40%,90.20%)和受精率(79.80%,80.07%,80.51%)均无统计学差异(P>0.05)。A组hCG注射日E2水平、获成熟卵数及优质胚胎数均显著高于B组和C组。3组患者每次移植的临床妊娠率(45.95%,43.97%,44.25%)、继续妊娠率(43.17%,40.91%,42.53%)、种植率(30.74%,27.78%,29.86%)及每位患者的累计妊娠率(CPR)(58.31%,53.60%,54.85%)均无统计学差异。3组的OHSS发生率很低(0.00%,0.14%,0.28%)。结论:对于卵巢中等与高反应患者,2 000 IU hCG与5 000 IU hCG在诱导卵泡的成熟中发挥同样的效果,2 000 IU hCG不仅不影响妊娠结局,而且阻止了OHSS的发生。 OBJECTIVE: To compare the effects of 2 000 IU, 3 000 IU low doses of hCG and 5 000 IU hCG on follicular ripening and subsequent frozen embryo transfer (FET) in controlled ovarian hyperstimulation (COH) Of pregnancy outcomes. Methods: The clinical data of 2,166 IVF / ICSI patients were retrospectively analyzed. According to the dose of hCG, the patients were divided into 3 groups: 2 000 IU (group A, n = 722), 3 000 IU (group B, n = 722 ), And 5 000 IU (group C, n = 722). The proportion of mature oocytes, fertilization rate, clinical pregnancy rate, cumulative pregnancy rate and the incidence of ovarian hyperstimulation syndrome (OHSS) were compared. Results: There was no significant difference in the percentage of mature oocytes (89.92%, 91.40%, 90.20%) and fertilization rate (79.80%, 80.07%, 80.51%) between the three groups (P> 0.05). The E2 level, the number of mature eggs and the number of high quality embryos in group A on hCG injection day were significantly higher than those in group B and C. The clinical pregnancy rate (45.95%, 43.97%, 44.25%), the continuous pregnancy rate (43.17%, 40.91%, 42.53%), the implantation rate (30.74%, 27.78%, 29.86% The cumulative pregnancy rate (CPR) of patients (58.31%, 53.60%, 54.85%) had no statistical difference. The incidence of OHSS in the three groups was very low (0.00%, 0.14%, 0.28%). CONCLUSIONS: 2 000 IU hCG and 5 000 IU hCG exert similar effects in inducing follicle maturation in moderate and high-response ovarian patients, and 2 000 IU hCG not only does not affect pregnancy outcomes but also prevents OHSS.